Spevigo 450 mg/7,5 ml (60 mg/ml) , Konzentrat zur Herstellung einer Infusionslösung
7680686250017
CH-68625
Konzentrat
Associated product:
SPEVIGO conc perf 450 mg/7.5ml 2 flac 7.5 ml
1 / 3
google
Article details
- Package size
- 2
- Selling units
- 2
- Measure
- Durchstechflasche(n)
- Galenic form
- Konzentrat
- Galenic group
- Tinkturen/Desinfektion
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
450.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
386.0 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
6.8 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 16701.95
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/01/2025
Authorization holder
Boehringer Ingelheim (Schweiz) GmbH
4057 Basel
Authorization information
- Swissmedic authorization number
- 68625
- Drug name
- Spevigo, Konzentrat zur Herstellung einer Infusionslösung
- Galenic form
- KOINF
- ATC Code
- L04AC22
- Authorization status
- B
- Dispensing category
- A
- First authorization
- 09/08/2023
- Authorization expiration date
- 21/05/2026
- IT Number
- 07.15.0.
- Domain
- Human medicine
Package details
- Description (FR)
- SPEVIGO conc perf 450 mg/7.5ml 2 flac 7.5 ml
- Description (DE)
- SPEVIGO Inf Konz 450 mg/7.5ml 2 Durchstf 7.5 ml
- Market launch
- 09/08/2023
- Narcotic (BTM)
- No